171 related articles for article (PubMed ID: 25823924)
1. NF2 blocks Snail-mediated p53 suppression in mesothelioma.
Cho JH; Lee SJ; Oh AY; Yoon MH; Woo TG; Park BJ
Oncotarget; 2015 Apr; 6(12):10073-85. PubMed ID: 25823924
[TBL] [Abstract][Full Text] [Related]
2. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
3. Loss of NF2 Induces TGFβ Receptor 1-mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome.
Cho JH; Oh AY; Park S; Kang SM; Yoon MH; Woo TG; Hong SD; Hwang J; Ha NC; Lee HY; Park BJ
Mol Cancer Ther; 2018 Nov; 17(11):2271-2284. PubMed ID: 30135214
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of CRISPR/Cas9-mediated NF2
Wahiduzzaman M; Karnan S; Ota A; Hanamura I; Murakami H; Inoko A; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y
Cancer Sci; 2019 Jan; 110(1):180-193. PubMed ID: 30417500
[TBL] [Abstract][Full Text] [Related]
5. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
7. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Shapiro IM; Kolev VN; Vidal CM; Kadariya Y; Ring JE; Wright Q; Weaver DT; Menges C; Padval M; McClatchey AI; Xu Q; Testa JR; Pachter JA
Sci Transl Med; 2014 May; 6(237):237ra68. PubMed ID: 24848258
[TBL] [Abstract][Full Text] [Related]
8. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
9. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
Singh A; Bhattacharyya N; Srivastava A; Pruett N; Ripley RT; Schrump DS; Hoang CD
Mol Ther; 2019 Sep; 27(9):1665-1680. PubMed ID: 31227395
[TBL] [Abstract][Full Text] [Related]
10. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses
Cooper J; Xu Q; Zhou L; Pavlovic M; Ojeda V; Moulick K; de Stanchina E; Poirier JT; Zauderer M; Rudin CM; Karajannis MA; Hanemann CO; Giancotti FG
Mol Cancer Ther; 2017 Aug; 16(8):1693-1704. PubMed ID: 28468780
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.
Ou WB; Lu M; Eilers G; Li H; Ding J; Meng X; Wu Y; He Q; Sheng Q; Zhou HM; Fletcher JA
Br J Cancer; 2016 Nov; 115(10):1253-1263. PubMed ID: 27736841
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
13. NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
Sato T; Sekido Y
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587439
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
Menges CW; Kadariya Y; Altomare D; Talarchek J; Neumann-Domer E; Wu Y; Xiao GH; Shapiro IM; Kolev VN; Pachter JA; Klein-Szanto AJ; Testa JR
Cancer Res; 2014 Feb; 74(4):1261-1271. PubMed ID: 24371224
[TBL] [Abstract][Full Text] [Related]
15. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
16. A new p53 target gene, RKIP, is essential for DNA damage-induced cellular senescence and suppression of ERK activation.
Lee SJ; Lee SH; Yoon MH; Park BJ
Neoplasia; 2013 Jul; 15(7):727-37. PubMed ID: 23814485
[TBL] [Abstract][Full Text] [Related]
17. ADP sensitizes ZL55 cells to the activity of cisplatin.
Muscella A; Cossa LG; Vetrugno C; Antonaci G; Marsigliante S
J Cell Physiol; 2019 Apr; 234(4):4409-4417. PubMed ID: 30144378
[TBL] [Abstract][Full Text] [Related]
18. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.
Andujar P; Lecomte C; Renier A; Fleury-Feith J; Kheuang L; Daubriac J; Janin A; Jaurand MC
Carcinogenesis; 2007 Jul; 28(7):1599-605. PubMed ID: 17272307
[TBL] [Abstract][Full Text] [Related]
20. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
